A comparative analysis of the phase III ASCENT-03 and TROPION-Breast02 trials finds that first-line TROP2-targeting antibody–drug conjugates improve progression-free survival compared with standard chemotherapy in patients with immunotherapy-ineligible metastatic triple-negative breast cancer. The synthesis emphasizes consistent PFS signals across both clinical programs. The pooled cross-trial comparison focuses on how these ADCs perform in settings where immunotherapy is not an option, highlighting an opportunity for targeted treatment in a historically limited segment of TNBC. For clinical development, the analysis supports continued investment in ADC positioning relative to chemotherapy backbones and reinforces the centrality of TROP2 targeting as a regimen differentiator. The main value for biotech teams is practical: it narrows the competitive decision space for next-line sequencing and potentially informs payer and guideline discussions around first-line use.